108 related articles for article (PubMed ID: 4027754)
41. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.
Eagan RT; Ames MM; Powis G; Kovach JS
Cancer Treat Rep; 1982 Feb; 66(2):283-7. PubMed ID: 7034934
[TBL] [Abstract][Full Text] [Related]
42. Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.
de Jager R; Brugarolas A; Hansen H; Cavalli F; Ryssel H; Siegenthaler P; Clarysse A; Renard J; Kenis Y; Alberto P
Eur J Cancer (1965); 1979 Jul; 15(7):971-4. PubMed ID: 385328
[No Abstract] [Full Text] [Related]
43. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT
Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial of dianhydrogalactitol in the treatment of children with refractory childhood malignancies: a report from the Children's Cancer Study Group.
Finklestein JZ; Shore N; Krivit W; Hammond D; Higgins G
Cancer Treat Rep; 1985 Nov; 69(11):1331-3. PubMed ID: 4092198
[No Abstract] [Full Text] [Related]
45. Phase II clinical trial of dianhydrogalactitol for remission induction in children with acute leukemia: a Southwest Oncology Group Study.
Vats TS; Lui V; Trueworthy R; van Eys J
Cancer Treat Rep; 1981; 65(1-2):121-2. PubMed ID: 6939482
[No Abstract] [Full Text] [Related]
46. Metastatic retinoblastoma and L-phenylalanine mustard-dianhydrogalactitol.
Helson L; Kitchin FD; Abramson D; Ellsworth RM
Anticancer Res; 1982; 2(4):235-8. PubMed ID: 7149653
[TBL] [Abstract][Full Text] [Related]
47. Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
Creagan ET; Eagan RT; Rubin J
Med Pediatr Oncol; 1979; 7(2):179-80. PubMed ID: 502975
[No Abstract] [Full Text] [Related]
48. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.
Hahn RG; Bauer M; Wolter J; Creech R; Bennett JM; Wampler G
Cancer Treat Rep; 1979 Mar; 63(3):513-5. PubMed ID: 371804
[TBL] [Abstract][Full Text] [Related]
49. Flow cytometric and molecular analysis of proliferative activity and DNA content in neuroblastoma: presence of stationary cells in S-phase.
Dominici C; Negroni A; Romeo A; McDowell H; Padula A; Pucci S; Cappelli C; Castello MA; Raschellà G
Anticancer Res; 1992; 12(1):59-63. PubMed ID: 1567182
[TBL] [Abstract][Full Text] [Related]
50. Dianhydrogalactitol in the treatment of children with primary brain tumors.
Weinblatt ME; Ortega JA; Giggins GR; Siegel SE
Cancer Treat Rep; 1981; 65(9-10):923-4. PubMed ID: 7273030
[No Abstract] [Full Text] [Related]
51. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.
Creagan ET; Eagan RT; Kvols LK
Oncology; 1981; 38(5):260-1. PubMed ID: 7196561
[TBL] [Abstract][Full Text] [Related]
52. Dianhydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix.
Vogl SE; Seltzer V; Camacho F; Calanog A
Cancer Treat Rep; 1982 Oct; 66(10):1809-12. PubMed ID: 6889913
[TBL] [Abstract][Full Text] [Related]
53. Inhibitory effects of fucoxanthin, a natural carotenoid, on N-myc expression and cell cycle progression in human malignant tumor cells.
Okuzumi J; Nishino H; Murakoshi M; Iwashima A; Tanaka Y; Yamane T; Fujita Y; Takahashi T
Cancer Lett; 1990 Nov; 55(1):75-81. PubMed ID: 2245414
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of dianhydrogalactitol in advanced soft tissue and bony sarcomas: a Southwest Oncology Group study.
Thigpen JT; Samson MK
Cancer Treat Rep; 1979 Apr; 63(4):553-5. PubMed ID: 445509
[No Abstract] [Full Text] [Related]
55. Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.
Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK
Cancer Treat Rep; 1981; 65(5-6):517-9. PubMed ID: 7195306
[No Abstract] [Full Text] [Related]
56. Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD; Scott M
Cancer Treat Rep; 1982 Aug; 66(8):1647-9. PubMed ID: 7105055
[No Abstract] [Full Text] [Related]
57. Complex evaluation of the effect of some cytostatic hexitol derivatives.
Holczinger L; Somfai-Relle S; Institoris E; Gáti E; Turi G
Oncology; 1980; 37 Suppl 1():104-8. PubMed ID: 7454197
[TBL] [Abstract][Full Text] [Related]
58. Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Di Vinci A; Geido E; Infusini E; Giaretti W
Int J Cancer; 1994 Nov; 59(3):422-6. PubMed ID: 7927952
[TBL] [Abstract][Full Text] [Related]
59. [Effects of 1,2:5,6-dianhydrogalactitol on the bone marrow stem cells in normal and melanoma-bearing mice (author's transl)].
Fan YJ; Li M; Zhou J
Zhongguo Yao Li Xue Bao; 1980 Dec; 1(2):112-5. PubMed ID: 6461181
[No Abstract] [Full Text] [Related]
60. BrdUrd/DNA flow cytometry analysis demonstrates cis-diamminedichloroplatinum (II)-induced multiple cell-cycle modifications on human lung carcinoma cells.
Demarcq C; Bastian G; Remvikos Y
Cytometry; 1992; 13(4):416-22. PubMed ID: 1526199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
